Search research articles
Contact Us
Filters
Showing results (1-10 of 43) with videos related to
Page
of 5
Sort By:
The Lancet. Oncology
|
August 12, 2016
Timing of androgen-deprivation therapy for prostate cancer: still a long way to go - Authors' reply
Gillian M Duchesne
The Lancet. Oncology
|
February 17, 2019
Effective and well tolerated: where do these drugs fit now?
Gillian M Duchesne
BJU International
|
July 23, 2014
The 'Timing of Androgen-Deprivation therapy in incurable prostate cancer' protocol (TOAD)--where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial
Gillian M Duchesne, Henry H Woo
The Lancet. Oncology
|
December 7, 2017
Timing of androgen-deprivation therapy in prostate cancer - Author's reply
Gillian M Duchesne, Henry H Woo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2006
How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer
Gillian M Duchesne, Rodney Syme, Deborah Howell
International Journal of Radiation Oncology, Biology, Physics
|
September 9, 2014
Around the globe--Radiation oncology in Australia
Gillian M Duchesne, Sandra L Turner, Sonja Cronje
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2015
In reply to Jenkins
Gillian M Duchesne, Sonja Cronje, Sandra L Turner
Australasian Radiology
|
November 28, 2002
Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: influence of V150 and V200 parameters
Gillian M Duchesne, Ram Das, Warren Toye, et al.
Journal of Medical Imaging and Radiation Oncology
|
March 9, 2011
Imaging, radiation oncology and randomised trials: time for a change?
Gillian M Duchesne, Shih-Chang Wang, Rodney J Hicks
Acta Oncologica (Stockholm, Sweden)
|
August 12, 2004
Trends in the use of androgen deprivation in prostate cancer
Eeva K Salminen, Jan-Erik Wickström, Tero Vahlberg, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 43) with videos related to
Sort By:
Page
of 5
The Lancet. Oncology
|
August 12, 2016
Timing of androgen-deprivation therapy for prostate cancer: still a long way to go - Authors' reply
Gillian M Duchesne
The Lancet. Oncology
|
February 17, 2019
Effective and well tolerated: where do these drugs fit now?
Gillian M Duchesne
BJU International
|
July 23, 2014
The 'Timing of Androgen-Deprivation therapy in incurable prostate cancer' protocol (TOAD)--where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial
Gillian M Duchesne, Henry H Woo
The Lancet. Oncology
|
December 7, 2017
Timing of androgen-deprivation therapy in prostate cancer - Author's reply
Gillian M Duchesne, Henry H Woo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2006
How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer
Gillian M Duchesne, Rodney Syme, Deborah Howell
International Journal of Radiation Oncology, Biology, Physics
|
September 9, 2014
Around the globe--Radiation oncology in Australia
Gillian M Duchesne, Sandra L Turner, Sonja Cronje
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2015
In reply to Jenkins
Gillian M Duchesne, Sonja Cronje, Sandra L Turner
Australasian Radiology
|
November 28, 2002
Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: influence of V150 and V200 parameters
Gillian M Duchesne, Ram Das, Warren Toye, et al.
Journal of Medical Imaging and Radiation Oncology
|
March 9, 2011
Imaging, radiation oncology and randomised trials: time for a change?
Gillian M Duchesne, Shih-Chang Wang, Rodney J Hicks
Acta Oncologica (Stockholm, Sweden)
|
August 12, 2004
Trends in the use of androgen deprivation in prostate cancer
Eeva K Salminen, Jan-Erik Wickström, Tero Vahlberg, et al.
Page
of 5